Skip to main content

Table 4 The adjusted association between 60-day mortality and cystatin C overall and stratified by AKI status

From: Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy

 

OR (95% CI)

p value

Full cohort (n = 919) covariates: sepsis, age, sex, APACHE III, AKI, treatment arm, LCA subphenotype⍺

 Cystatin C

Q2

1.1 (0.6–1.8)

0.0002

Q3

1.8 (1.1–3.1)

Q4

2.5 (1.5–4.2)

With acute kidney injury (n = 486) covariates: sepsis, age, sex, APACHE III, treatment arm, LCA subphenotype⍺

 Cystatin C

Q2

1.2 (0.6–2.6)

0.0032

Q3

2.6 (1.3–4.9)

Q4

2.7 (1.4–5.3)

Without acute kidney injury (n = 433) covariates: sepsis, age, sex, APACHE III, treatment arm, LCA subphenotype⍺

 Cystatin C

Q2

0.7 (0.3–1.6)

0.094

Q3

0.9 (0.4–2.2)

Q4

2.0 (0.8–5.2)

  1. p value refers to post-estimation linear test for trend across cystatin C quartiles
  2. AKI acute kidney injury by Kidney Disease: Improving Global Outcomes (KDIGO) creatinine-based definition
  3. ⍺LCA latent class analysis, Famous et al. [12]
  4. All analyses compare stated quartile to first quartile (Q1)
Back to article page

Critical Care

ISSN: 1364-8535